[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-280650-105":53,"doc-detail-280650-en":126},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":119,"head_meta":121,"extra_data":123,"updated_unix":125},105,"en","entyvio-vedolizumab-prior-authorization-pa-denial-and-appeal-checklist-sample-letter","Entyvio (vedolizumab) Prior Authorization (PA) Denial and Appeal Checklist - Sample Letter","","Prior authorization (PA) denial and appeal guidance for Entyvio (vedolizumab) in moderately to severely active ulcerative colitis or Crohn’s disease. Provides a sample appeal letter addressed to the medical director, including required patient and case details, diagnosis history, and clinical rationale. Outlines steps to review denial reasons, gather supporting documents, track appeal timelines, pursue successive appeal levels, and consider supervisor help, exceptions, complaints, or external review. Includes important safety information and contraindications for Entyvio.",{"@graph":63,"@context":118},[64,80,101],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":41,"@type":70,"position":76},"https://docshare.wps.com/template/letters/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/entyvio-vedolizumab-prior-authorization-pa-denial-and-appeal-checklist-sample-letter/280650/",4,{"url":78,"name":59,"@type":81,"image":82,"author":87,"headline":59,"publisher":90,"fileFormat":93,"inLanguage":57,"description":61,"dateModified":94,"datePublished":95,"encodingFormat":93,"isAccessibleForFree":96,"interactionStatistic":97},"DigitalDocument",{"url":83,"@type":84,"width":85,"height":86},"https://docshare.wps.com/thumbnails/entyvio-vedolizumab-prior-authorization-pa-denial-and-appeal-checklist-sample-letter/280650.png","ImageObject",442,249,{"name":88,"@type":89},"Ava Thompson","Person",{"url":68,"name":91,"@type":92},"DocShare","Organization","application/pdf","2026-10-23","2026-09-16",true,{"@type":98,"interactionType":99,"userInteractionCount":20},"InteractionCounter",{"@type":100},"ViewAction",{"@type":102,"mainEntity":103},"FAQPage",[104,110,114],{"name":105,"@type":106,"acceptedAnswer":107},"What should the Entyvio PA denial appeal letter include?","Question",{"text":108,"@type":109},"It should include patient and case details, the denial reference (case ID and health plan information), the indication and relevant diagnosis history, and a medical rationale explaining why Entyvio is warranted and medically necessary. It should also reference the specific denial reason(s) from the health plan.","Answer",{"name":111,"@type":106,"acceptedAnswer":112},"How can a patient respond if the appeal decision is not received within 30 days?",{"text":113,"@type":109},"Contact the health plan to confirm the appeal letter was received and ask for status updates. The document also notes that an urgent review may be available upon request.",{"name":115,"@type":106,"acceptedAnswer":116},"What safety information is highlighted for Entyvio?",{"text":117,"@type":109},"Entyvio is contraindicated in patients with known serious or severe hypersensitivity to Entyvio or its excipients. The document also warns about infusion-related reactions, increased infection risk, and rare progressive multifocal leukoencephalopathy (PML), advising monitoring for new or worsening neurological signs.","https://schema.org",{"og:url":78,"og:type":120,"og:title":59,"og:site_name":91,"og:description":61},"article",{"robots":122,"canonical":78},"index,follow",{"doc_id":124,"site_id":56},280650,1790454759,{"code":4,"msg":5,"data":127},{"doc_id":124,"user_id":128,"nickname":88,"user_avatar":129,"doc_module":9,"category_id":40,"category_name":41,"doc_title":59,"doc_description":61,"doc_content":130,"file_id":131,"file_url":132,"file_type":133,"file_size":134,"view_count":20,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":73,"language":135,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":136,"faqs":137,"seo_title":138,"seo_description":61,"update_tm":139,"read_time":9},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","PRIOR AUTHORIZATION (PA) DENIAL AND APPEAL CHECKLIST  \n| Sample Letter of Appeal for Entyvio\u003Cbr>[Physician’s letterhead]\u003Cbr>[Date] [Patient’s name]\u003Cbr>[Health plan’s name] [Date of birth]\u003Cbr>ATTN: [Department] [Case ID number]\u003Cbr>[Medical director’s name] [Dates of service]\u003Cbr>[Health plan’s address][City, State ZIP]\u003Cbr>Re: Appeal of Denial for Entyvio® (vedolizumab)\u003Cbr>Dear [Medical director’s name],\u003Cbr>I am writing to request reconsideration of your denial of coverage for Entyvio, which I have prescribed for [patient’s name] . I have read and acknowledged your policy for responsible management of drugs for [Crohn's disease (CD)/ulcerative colitis (UC)] [insert appropriate ICD-10-CM code here] . Your reason(s) for the denial [is/are][reason(s) for the denial] .\u003Cbr>Based on the patient’s condition and medical history, as well as my experience treating patients with [CD/UC], I believe treatment with Entyvio is warranted, appropriate, and medically necessary in this case. Please see my clinical reasoning below.\u003Cbr>Patient diagnosis and medical history in support of the appeal\u003Cbr>[Patient’s name] is [a/an] [age]-year-old [male/female] patient who has been diagnosed with [CD/UC] as of [date of diagnosis] . [He/she] has been in my care since [date] .\u003Cbr>[Include relevant medical information to support your reason for treatment with Entyvio. An example may include evidence that the patient’s symptoms and disease activity have been progressing despite treatments with a tumor necrosis factor (TNF) blocker, immunomodulators, or corticosteroids. Additional information needed may include:\u003Cbr>• Supporting documentation as requested by the plan in their denial letter\u003Cbr>• Discussion of clinical attributes of Entyvio and relevance to the patient\u003Cbr>• Review of previous therapy\u003Cbr>• Your recommendations for why Entyvio is appropriate for this patient] |  |\n| --- | --- |\n|  |  |\n\nFOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS OR CROHN’S DISEASE  \nPA denials and appeals vary by health plan. These processes can be conducted through letter correspondence, fax, or peer-to-peer discussion.  \nThe information below may be helpful in appealing a PA denial.  \nIf the health plan has denied a PA for Entyvio:  \no Review the denial notification so your appeal can address the specific reasons for the denial  \no Contact the insurer if you have not received a denial explanation  \no Confirm with the insurer where the appeal should be sent  \no Confirm any deadlines  \no Gather the necessary documents and information (eg, chart details, lab values, anything applicable to the specific reason for denial)  \nIf you or your patient have not received a decision within 30 days:  \no Contact the health plan to confirm that the appeal letter was received and ask about its status  \no An urgent review of the appeal may be available upon request If the first appeal was denied:  \no Contact the health plan to understand the next level of appeal and if any additional information is required  \nIf the appeal process has been exhausted with the insurer, consider the following alternatives:  \no Ask for a supervisor or manager to assist  \no Ask for a one-time exception  \no File a complaint with the state’s insurance commissioner  \no Submit a request for an external review  \nPlease contact your Field Reimbursement Manager or EntyvioConnect if you need additional support at any step in the process.  \nPlease see Indications and Important Safety Information on the next page.  \nSAMPLE LETTER OF APPEAL  \nVisit [EntyvioHCP.com/Access-Support](EntyvioHCP.com/Access-Support)[ ](EntyvioHCP.com/Access-Support)to download this template to help with appealing a PA denial.  \n1-855-ENTYVIO (1-855-368-9846)  \nMonday to Friday, from  \n8 am to 8 pm ET (except holidays)  \n[EntyvioHCP.com/Access-Support](EntyvioHCP.com/Access-Support)  \nIMPORTANT SAFETY INFORMATION  \n• ENTYVIO (vedolizumab) for injection is contraindicated in patients who have had a known serious or severe hypersens","cbCaidksejYC1mKC","https://ap.wps.com/l/cbCaidksejYC1mKC","pdf",263373,"English","# PRIOR AUTHORIZATION (PA) DENIAL AND APPEAL CHECKLIST\n## Sample Letter of Appeal\n## Tips for Patients When Appealing a PA Denial\n## Important Safety Information","[{\"question\":\"What should the Entyvio PA denial appeal letter include?\",\"answer\":\"It should include patient and case details, the denial reference (case ID and health plan information), the indication and relevant diagnosis history, and a medical rationale explaining why Entyvio is warranted and medically necessary. It should also reference the specific denial reason(s) from the health plan.\"},{\"question\":\"How can a patient respond if the appeal decision is not received within 30 days?\",\"answer\":\"Contact the health plan to confirm the appeal letter was received and ask for status updates. The document also notes that an urgent review may be available upon request.\"},{\"question\":\"What safety information is highlighted for Entyvio?\",\"answer\":\"Entyvio is contraindicated in patients with known serious or severe hypersensitivity to Entyvio or its excipients. The document also warns about infusion-related reactions, increased infection risk, and rare progressive multifocal leukoencephalopathy (PML), advising monitoring for new or worsening neurological signs.\"}]","Entyvio (vedolizumab) Prior Authorization (PA) Denial and Appeal Checklist - Sample Letter | PDF",1789553575]